Bringing the Oncology Community Together

Supercomputer Network Allows for Faster Genomic Analysis

Andrew J. Roth
Published Online: Thursday, October 4, 2012
Dr. Patrick Soon-Shiong

Patrick Soon-Shiong, MD

A new supercomputer-based network will allow physicians to transfer and analyze genomic data more rapidly than standard methods, announced Patrick Soon-Shiong, MD, Chairman of NantHealth and the Chan Soon-Shiong Institute for Advanced Health, on October 3.

“It currently takes approximately two months and tens of thousands of dollars to perform the sequencing and analysis of a single cancer patient’s genome," said Soon-Shiong. "We needed a national supercomputing infrastructure that brings genomic medicine into clinical practice. By placing supercomputers in the hands of physicians, that need is now a reality.”

The high-speed network was built through the collaboration of multiple technology and healthcare companies and organizations with the intent to provide physicians the ability to analyze genetics, risk, and costs of multiple treatment options, in an accelerated timeframe.

In an analysis of the system, 6017 tumor and germline exomes from 3022 patients were transferred and processed by the supercomputer using a fiber network. Samples for the analysis primarily represented solid tumors. In total, 96,512 gigabytes of genetic information were analyzed.

The test of the system measured the total time needed for transferring the data and analyzing the results. In general, the overall transfer speed for each sample was 17.4 seconds and each analysis was completed in approximately 47 seconds. 

“Doctors will finally be able to provide higher-quality treatment in a dramatically more efficient, effective, and affordable manner," Soon-Shiong said in a release. "This revolution in healthcare is long overdue - converging 21st century medical science with 21st century technology.”

NantHealth built the supercomputing network in collaboration with Blue Shield of California, the Chan Soon-Shiong Institute for Advanced Health, the National LambdaRail, Doctors Helping Doctors, Verizon, Bank of America, AT&T, Intel, and Hewlett-Packard.
Related Articles
The majority of the new oncology drugs approved in 2012 are oral agents, and by reviewing the indications for these agents, it’s easy to see how genetics impacts the agent’s efficacy.
An interview with Alice Tsang Shaw, MD, PhD, who has won broad recognition for her contributions to the treatment of NSCLC, including the use of crizotinib to target the ROS1 gene rearrangement and research into other emerging agents.
A large proportion of patients become rituximab-refractory, which has prompted the development of newer CD20 agents with altered structures that are designed to improve upon rituximab’s performance.
Most Popular Right Now
Physicians' Education Resource
External Resources

American Journal of Managed Care
HCPLive
PainLive
Pharmacy Times
Physicians' Education Resource
Physician's Money Digest
Specialty Pharmacy Times
TargetedHC
OncLive Resources

Archives
Blogs
OncLive TV
Oncology Nurses
Publications
Specialties
Web Exclusives


About Us
Advertise
Advisory Board
Contact Us
Forgot Password
Privacy Policy
Terms & Conditions
Intellisphere, LLC
666 Plainsboro Road
Building 300
Plainsboro, NJ 08536
P: 609-716-7777
F: 609-716-4747

Copyright OncLive 2006-2013
Intellisphere, LLC. All Rights Reserved.